Word

Status

Pending

Status Code

688

Status Date

Tuesday, March 26, 2024

Serial Number

97844288

Mark Type

2000

Filing Date

Friday, March 17, 2023

Published for Opposition

Tuesday, January 30, 2024

Trademark Owner History

Crinetics Pharmaceuticals, Inc. - Owner At Publication

Classifications

5 Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine related diseases; pharmaceutical preparations for targeting neuropeptide receptors; pharmaceutical preparations for the treatment of cancer, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, carcinoid syndrome, congenital adrenal hyperplasia, hypercalcemia, chronic pain, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic preparations for the treatment of ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders

42 Medical research services; scientific research and development; pharmaceutical research and development; therapeutic research and development, namely, research and development of therapeutic preparations; research and development in the field of oncology; medical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; pharmaceutical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic research, namely, research of therapeutic preparations for ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and therapeutics

The mark consists of dot and line spirograph design in the shape of a half circle.

Trademark Events

Mar 26, 2024

Noa E-Mailed - Sou Required From Applicant

Feb 28, 2024

Teas Change Of Correspondence Received

Feb 28, 2024

Applicant/Correspondence Changes (Non-Responsive) Entered

Feb 28, 2024

Teas Change Of Owner Address Received

Jan 30, 2024

Official Gazette Publication Confirmation E-Mailed

Jan 30, 2024

Published For Opposition

Jan 10, 2024

Notification Of Notice Of Publication E-Mailed

Dec 22, 2023

Approved For Pub - Principal Register

Oct 9, 2023

Preliminary/Voluntary Amendment - Entered

Dec 19, 2023

Examiner's Amendment Entered

Dec 19, 2023

Assigned To Lie

Dec 18, 2023

Notification Of Examiners Amendment E-Mailed

Dec 18, 2023

Examiners Amendment E-Mailed

Dec 18, 2023

Examiners Amendment -Written

Dec 13, 2023

Assigned To Examiner

Oct 9, 2023

Teas Voluntary Amendment Received

Apr 11, 2023

Notice Of Design Search Code E-Mailed

Apr 9, 2023

New Application Office Supplied Data Entered

Mar 21, 2023

New Application Entered